Mark Nuijten

Malnutrition in healthcare: treatment pays off

Valuation of Innovative Drugs at ISPOR 2023 in Copenhagen

Integrated Valuation Model - V4A2M Model

Mark Nuijten EPA 2021

An innovative pricing model to assess the price of expensive drugs with an orphan indication

Lees meer

Innovation Premium for Innovative Orphan Drugs in Oncology and Rare Diseases

Guest lecture for Colombian American Chamber of Commerce on Pricing Policy for Orphan Drugs

Milestone of more than 10’000 views on our policy paper challenging the ICER

International Market Access Update

Economic impact of macrosomia

Increasing interest in our Pricing Model and Algorithm for "expensive" drugs

The true prices of drugs

A2M - Minerva in Vienna at ISPOR

Presentation of NICE model at European Hematology Association

ISPOR Vienna

Evaluation and valuation of ultra-innovative drugs: a new concept

Economics of obesity

Valuation tool for biotechnology

Valuation of innovation

Policy consultancy for Ministry of Health in The Netherlands

Annual Meeting DGO in Berlin